A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α‐reductase inhibitors GI198745 and finasteride

@article{Gisleskog1998AMF,
  title={A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α‐reductase inhibitors GI198745 and finasteride},
  author={P. O. Gisleskog and D. Hermann and M. Hammarlund-Udenaes and M. Karlsson},
  journal={Clinical Pharmacology & Therapeutics},
  year={1998},
  volume={64}
}
  • P. O. Gisleskog, D. Hermann, +1 author M. Karlsson
  • Published 1998
  • Chemistry, Medicine
  • Clinical Pharmacology & Therapeutics
    • To develop a pharmacokinetic‐pharmacodynamic model that characterizes the conversion of testosterone to dihydrotestosterone (DHT) by 5α‐reductase types 1 and 2 and the irreversible inhibition of 5α‐reductase by finasteride, a 5α‐reductase type 2 inhibitor and by GI198745 (dutasteride), a potent and specific dual 5α‐reductase inhibitor. 
    View on Wiley
    ncbi.nlm.nih.gov
    54 Citations
    Highly Influential Citations
    3
    Background Citations
    13
    Methods Citations
    2
    54 Citations
    Citation Type

    Citation Type

    PHARMACODYNAMICS AND PHARMACOKINETICS 5 á-Reductase Isozyme Sensitivity to Finasteride : Species Differences
    • Highly Influenced
    • PDF
    A New Look at the 5á-Reductase Inhibitor Finasteride
    • 31
    A new look at the 5alpha-reductase inhibitor finasteride.
    • 117
    Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics.
    • 11
    Validation of a population pharmacokinetic/pharmacodynamic model for 5α-reductase inhibitors
    • 14
    Glucocorticoid metabolism and activation
    Estimating the contribution of the prostate to blood dihydrotestosterone.
    • 30
    • PDF
    The effect of 5 alpha-reductase inhibitors on erectile function.
    • 32
    Finasteride in the treatment of alopecia
    • 69
    • Highly Influenced
    The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination.
    • 40
    • PDF

    References

    SHOWING 1-10 OF 32 REFERENCES
    Pharmacodynamic Modeling of Finasteride, a 5α‐Reductase Inhibitor
    • 11
    Hormonal effects of an orally active 4‐azasteroid inhibitor of 5α‐reductase in humans
    • 89
    Finasteride: a slow-binding 5 alpha-reductase inhibitor.
    • 69
    Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR.
    • 135
    • PDF
    Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers.
    • 140
    Clinical Pharmacokinetics and Pharmacodynamics of Finasteride
    • 89
    Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies.
    • 62
    Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase.
    • 346
    5 alpha-metabolism in finasteride-treated subjects and male pseudohermaphrodites with inherited 5 alpha-reductase deficiency. A review.
    • 9
    17 beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5 alpha-reductase 1.
    • 44